Innovate Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase IIb clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase I clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease, as well as product for the treatment of alcoholic steatohepatitis (ASH).
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone919-275-1933
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$4.07 million
Profitability
Miscellaneous
Employees8
Next Earnings Date8/21/2019 (Estimated)
OptionableOptionable
Innovate Biopharmaceuticals (NASDAQ:INNT) Frequently Asked Questions
What is Innovate Biopharmaceuticals' stock symbol?
Innovate Biopharmaceuticals trades on the NASDAQ under the ticker symbol "INNT."
How were Innovate Biopharmaceuticals' earnings last quarter?
Innovate Biopharmaceuticals Inc (NASDAQ:INNT) released its earnings results on Monday, March, 18th. The company reported ($0.11) earnings per share for the quarter, meeting the Zacks' consensus estimate of ($0.11). View Innovate Biopharmaceuticals' Earnings History.
When is Innovate Biopharmaceuticals' next earnings date?
What price target have analysts set for INNT?
1 analysts have issued twelve-month price targets for Innovate Biopharmaceuticals' shares. Their predictions range from $35.00 to $35.00. On average, they expect Innovate Biopharmaceuticals' share price to reach $35.00 in the next twelve months. This suggests a possible upside of 2,917.2% from the stock's current price. View Analyst Price Targets for Innovate Biopharmaceuticals.
What is the consensus analysts' recommendation for Innovate Biopharmaceuticals?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innovate Biopharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Innovate Biopharmaceuticals.
What are Wall Street analysts saying about Innovate Biopharmaceuticals stock?
Here are some recent quotes from research analysts about Innovate Biopharmaceuticals stock:
- 1. According to Zacks Investment Research, "Innovate Biopharmaceuticals, Inc. is a clinical stage biotechnology company. It focused on developing novel medicines for autoimmune/ inflammatory disease. The company's pipeline includes drug candidates for celiac disease, an unmet need, and ulcerative colitis. Its products includes INN-202 for the treatment of Celiac Disease with fast track designation, INN-108 for Inflammatory Bowel Disorders, mild to moderate Ulcerative Colitis and a GI orphan disease in a convenient liquid formulation, INN-329 for Magnetic Resonance Cholangiopancreatography which are in clinical stages. Innovate Biopharmaceuticals Inc., formerly known as Monster Digital, Inc., is based in SIMI VALLEY, United States. " (10/17/2018)
- 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. We utilize a composite discounted cash flow (DCF)-based analysis methodology, which ascribes $750M to INN-202 in celiac disease (70% probability of success based on positive Phase 2b data and 15% discount rate), $400M to INN-108 in ulcerative colitis (65% probability of success and 12% discount rate), and $130M to another formulation of larazotide, designated INN-217, for treatment of NASH (35% probability of success, along with a 15% discount rate)." (8/1/2018)
Has Innovate Biopharmaceuticals been receiving favorable news coverage?
Media stories about INNT stock have trended somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Innovate Biopharmaceuticals earned a news impact score of 1.8 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Innovate Biopharmaceuticals.
Are investors shorting Innovate Biopharmaceuticals?
Innovate Biopharmaceuticals saw a increase in short interest in May. As of May 15th, there was short interest totalling 1,853,800 shares, an increase of 20.7% from the April 15th total of 1,536,000 shares. Based on an average daily trading volume, of 979,100 shares, the days-to-cover ratio is currently 1.9 days. Currently, 8.3% of the shares of the stock are short sold. View Innovate Biopharmaceuticals' Current Options Chain.
Who are some of Innovate Biopharmaceuticals' key competitors?
Some companies that are related to Innovate Biopharmaceuticals include Osmotica Pharmaceuticals (OSMT), Intec Pharma (NTEC), Northwest Biotherapeutics (NWBO), Kezar Life Sciences (KZR), REDHILL BIOPHAR/S (RDHL), Applied Therapeutics (APLT), Checkpoint Therapeutics (CKPT), Mustang Bio (MBIO), Trevi Therapeutics (TRVI), Aduro BioTech (ADRO), Menlo Therapeutics (MNLO), XOMA (XOMA), Tocagen (TOCA), Harrow Health (HROW) and Sesen Bio (SESN).
What other stocks do shareholders of Innovate Biopharmaceuticals own?
Who are Innovate Biopharmaceuticals' key executives?
Innovate Biopharmaceuticals' management team includes the folowing people:
- Mr. Sandeep Laumas M.D., CEO & Exec. Chairman (Age 50)
- Mr. Jay P. Madan M.S., Founder, Pres, Chief Bus. Officer, Interim Principal Fin & Accounting Officer and Director (Age 53)
- Dr. Christopher P. Prior, Consultant (Age 66)
- Jerry Gardner M.D., Head of Clinical Strategy
- Dr. Patrick H. Griffin, Chief Medical Officer (Age 64)
Who are Innovate Biopharmaceuticals' major shareholders?
Innovate Biopharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include SG Americas Securities LLC (0.05%). Company insiders that own Innovate Biopharmaceuticals stock include Christopher P Prior, Jay P Madan, June Sherie Almenoff, Roy Proujansky and Sandeep Laumas. View Institutional Ownership Trends for Innovate Biopharmaceuticals.
Which institutional investors are buying Innovate Biopharmaceuticals stock?
INNT stock was bought by a variety of institutional investors in the last quarter, including SG Americas Securities LLC. Company insiders that have bought Innovate Biopharmaceuticals stock in the last two years include Christopher P Prior, Jay P Madan, June Sherie Almenoff, Roy Proujansky and Sandeep Laumas. View Insider Buying and Selling for Innovate Biopharmaceuticals.
How do I buy shares of Innovate Biopharmaceuticals?
Shares of INNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Innovate Biopharmaceuticals' stock price today?
One share of INNT stock can currently be purchased for approximately $1.16.
How big of a company is Innovate Biopharmaceuticals?
What is Innovate Biopharmaceuticals' official website?
How can I contact Innovate Biopharmaceuticals?
Innovate Biopharmaceuticals' mailing address is 8480 HONEYCUTT ROAD SUITE 120, RALEIGH NC, 27615. The company can be reached via phone at 919-275-1933 or via email at [email protected]
MarketBeat Community Rating for Innovate Biopharmaceuticals (NASDAQ INNT)
MarketBeat's community ratings are surveys of what our community members think about Innovate Biopharmaceuticals and other stocks. Vote "Outperform" if you believe INNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
